{reportSlug=global-antifibrinolytic-drugs-market, reportId=100308, mktKeyword=Antifibrinolytic Drugs, cagr=0.00, publishDate=May 2023, priceOption2=7500, reportTitle=Antifibrinolytic Drugs Comprehensive Study by Drug Type (Amicar, Aminocaproic acid, Aprotinin, Cyklokapron, Fibrinogen, human, Lysteda, RiaSTAP, Tranexamic acid injection, Tranexamic acid oral, Trasylol), End-users (Hospitals, Ambulatory Surgical Centers, Clinics, Healthcare Specialty processes, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Indications (Gynecology (Menorrhagia, Pregnancy, Parturition, Gynecological surgery, Gastrointestinal (GI) bleeding, Dental surgery, Haemorrhage and Bleeding disorders), Hereditary angioedema, Fibrinolytic response testing, Surgeries (Cardiac, Orthopedic, Liver and Neurosurgery)) Players and Region - Global Market Outlook to 2028, baseYr=2022, totalTableFig=210, priceOption1=3750, forecastYr=2028, noOfPages=237, reportKey=99832, breadcrum=Global (United States, European Union and China) Antifibrinolytic Drugs}
We do not share your information with anyone. However, we may send you
emails based on your report interest from time to time. You may contact
us at any time to opt-out.
Select User Access Type
Key Highlights of Report
May 2023
237 Pages
86 Tables
Base Year: 2022Coverage: 15+ Companies; 18
Countries